Participated · Series D · Feb 2026

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on improving musculoskeletal health through innovative biologic treatments. Its pipeline currently features three clinical candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The company recently completed enrollment in its Phase 2 ARTEMIS trial of AGA2118 and has initiated dosing in the Phase 2 IDUN trial evaluating AGA2115. Proceeds from its latest financing will also advance these programs and other undisclosed pipeline assets. Headquartered in Westlake Village, California, Angitia leverages extensive bone biology expertise and rational drug design to address clear unmet medical needs in serious musculoskeletal diseases. No commercial products have been approved yet, reflecting the firm’s clinical-stage status.

Led · Series B · Apr 2023

Chamlion develops hardware-as-a-service (HaaS) dental 3D printing systems and a cloud printing service that connects data, design and manufacturing across the full dental workflow. The company transitioned from a traditional 3D printing equipment supplier to a cloud printing service model after rebranding from Chamlion Laser to Chamlion Technology in May 2021. Its product offering targets end-to-end dental digitalization, including a distributed dental manufacturing cloud factory and a digital service platform for the full process of dentistry. Chamlion reports installed capacity of more than 1,000 metal 3D printers, leading the dental 3D metal printing market. It has established branches in Vietnam, the United States, France and Turkey and built localized digital manufacturing centers and sales networks across multiple countries. The company plans to use new funding to expand domestic and overseas business and to promote and upgrade its existing product line to consolidate its position in dental digitalization.

Participated · Series B · Apr 2021

EdiGene develops proprietary genome-editing platforms, including ex vivo editing for hematopoietic stem cells and T cells, an in vivo RNA base-editing platform (LEAPER™), and high-throughput genome-editing screening to discover targeted therapies. The company’s lead candidate, ET-01 (a CRISPR/Cas9 therapy for transfusion-dependent β-thalassemia), received the first gene-editing and first hematopoietic stem cell therapy IND approval in China and is preparing for a Phase I trial. EdiGene is also advancing allogeneic CAR-T programs, in vivo RNA base-editing therapies, and other assets discovered via its screening platforms. Founded in 2015, the company is headquartered in Beijing and has offices/operations in Guangzhou, Shanghai and Cambridge, Massachusetts. Financially, EdiGene completed an RMB 400 million (approximately USD 62 million) Series B Plus financing and previously closed an RMB 450 million (approximately USD 67 million) Series B in October 2020. Proceeds from the new round will be used to advance pipeline candidates into the clinic and to scale up business operations, including newly opened clinical, business development, and R&D centers. EdiGene develops genome editing technologies and therapeutics across genetic diseases and oncology. Founded in 2015, the company has established four gene‑editing platforms: ex vivo platforms for hematopoietic stem cells and T cells, an in vivo RNA base‑editing platform, and high‑throughput genome‑editing screening. It opened a GMP manufacturing facility in Guangdong in 2018. EdiGene is advancing its early‑stage programs into clinical development and plans to use new proceeds to move its pipeline into clinics and expand the team. Financially, the company completed a RMB 450 million (approximately USD 67 million) Series B and reported having raised about RMB 700 million (USD 100 million) in the past two years. Headquarters are in Beijing, with subsidiaries in Guangzhou and Cambridge, Massachusetts. EdiGene translates genome‑editing technologies into novel therapeutics for a broad range of diseases and into solutions to advance drug discovery. The company leverages proprietary platforms to develop gene‑editing therapies and to perform high‑throughput genome screening. It has been building an allogeneic CAR‑T platform aimed at off‑the‑shelf T‑cell therapies. EdiGene recently formed a research collaboration with a clinical‑stage biopharmaceutical company to explore new allogeneic T‑cell therapeutic approaches for cancer; the partner and terms were not disclosed. The company completed an approximately $11 Million Series pre‑B2 financing with participation from IDG Capital and Lilly Asia Ventures. EdiGene was founded in 2015 and is headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA. EdiGene develops genome‑editing platforms to create novel therapeutics for genetic diseases and cancer and to enable high‑throughput genome screening for drug discovery. The company leverages proprietary gene‑editing technologies to advance therapeutic candidates toward clinical testing. It recently completed a financing round to support progression of its portfolio and clinic-directed activities. Management has been strengthened with the appointment of Yun Li, MD, as Vice President of Clinical Development to help advance hematology and oncology programs. EdiGene was founded in 2015 and is headquartered in Beijing, with operational subsidiaries in Guangzhou and Cambridge, Massachusetts. The company says the new financing validates and supports its strategy to translate platforms into potential therapeutics. EdiGene develops genome editing technologies into novel therapeutics for genetic diseases and cancer and builds high-throughput genome screening platforms to advance drug discovery. The company leverages proprietary platforms to develop gene-editing therapies and to conduct high-throughput screening that enables dissection of functional big data in biological contexts. EdiGene plans to continue advancing its portfolio of therapeutic programs and to further develop its High Throughput Genome Screening platforms into a comprehensive solution for partners in areas such as drug sensitivity, drug resistance and synthetic lethality. The company completed approximately $15 million in a Series pre-B financing to support these efforts. New investor Huagai Capital participated, along with Series A lead investor IDG Capital, Series A investor WI Harper Group and other insiders. Founded in 2015, EdiGene is headquartered in Beijing with operational subsidiaries in Guangzhou and Cambridge, Massachusetts.

Participated · Equity · Dec 2020

MicroTech Medical Co., Ltd. announced it raised CNY 575 million in a funding round on December 8, 2020. The capital was provided by a group of new and returning investors. The round was co-led by Tencent Holdings Ltd., IDG Capital Partners Co., Ltd., and Taikang Qianzhen Fund. Other participants included CICC Jia Cheng Investment Management, Sanzheng Health, China Everbright Limited (SEHK:165), Zhongjin Pucheng Investment, and 3H Health Investment Management. Returning investors included Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Lilly Asia Ventures, CD Capital, Shanghai Guofang FOF Equity Investment Management Co., Ltd., and Zhejiang Juren Capital Management Co., Ltd. The articles do not disclose use of proceeds, valuation, or operating metrics.

Participated · Series C · Dec 2019

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.